Used in research settings as a potent and selective inhibitor of the BET (bromodomain and extra-terminal) family of proteins, particularly targeting BRD4. This compound is utilized to study epigenetic regulation of gene expression, especially in the context of cancer and inflammatory diseases. It demonstrates strong anti-proliferative effects in hematological cancer cell lines and is employed to probe the role of BET proteins in transcriptional control. Due to its high selectivity and cellular permeability, GNF351 is valuable in preclinical studies aiming to understand chromatin dynamics and to develop targeted therapies.